knowledge -WSS

knowledge

author：knowledge 2025-09-30 16:24:32 - browse：757

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Addiction doctors spar with methadone clinics over legislation

WSS

Akero's treatment for NASH falls short in cirrhosis study

Heat waves linked to early deliveries, preterm births in new study

European regulators consider appeal over Amylyx ALS drug

There’s no way to know how good AI health technologies are

How doctors and nurses shape Google's AI

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Stigma and the return of syphilis

ChatGPT in medicine: STAT answers readers' burning questions

Akero's treatment for NASH falls short in cirrhosis study

Medical leaders decry Supreme Court decision on affirmative action

Researchers CRISPR chickens in bid to protect them from bird flu

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Lab trade group sues FDA to halt regulation of lab

Peter Hotez and the public health issue of online harassment

Heat waves linked to early deliveries, preterm births in new study

explore

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Humana CEO Bruce Broussard to step down in 2024

Dark money group runs ads on China biotech bill

A fraught question for the kids of Alzheimer’s: Is it coming for us?

AI used to predict Covid

Addiction doctors spar with methadone clinics over legislation

leisure time

explore

entertainment

leisure time